Evicenter
MarkdownMedical informationP&T meetings
Psilocybin (COMP360)

Treatment-resistant depression

Manufacturer
COMPASS Pathways
Last updated
261 sources

Clinical evidence

COMP003

41 evidence topics · 2 sources

Objective
Location and study date
Registry dates and locations
FieldRegistry entry
Study start (actual)“2020-08-10”
Primary completion (actual)“2021-10-14”
Study completion (actual)“2021-10-14”
United States site“Kadima Neuropsychiatry Institute”
Ireland site“Sheaf House, Tallaght Hospital”
Study design
Eligibility criteria
Treatment
Single 25 mg dose during a monitored session
Study outcomes
Rationale for using montgomery-åsberg depression rating scale total score as the primary endpoint
Statistical analysis description
Number of participants (Planned and analyzed)
Registry enrollment
FieldRegistry entry
Enrollment (actual)“19”
Description of analysis sets
Results
Participant disposition
Baseline characteristics
Demographic and clinical characteristics, safety analysis set
CharacteristicCOMP360 25 mg + SSRI (N = 19)
Female, n (%)“13 (68.4)”View highlighted excerpt for this quote
Age, years, mean (SD)“42.2 (10.80)”View highlighted excerpt for this quote
Race, White, n (%)“15 (78.9)”View highlighted excerpt for this quote
Body mass index, kg/m2, mean (SD)“26.26 (6.521)”View highlighted excerpt for this quote
Duration of current episode 1 year to <2 years, n (%)“13 (68.4)”View highlighted excerpt for this quote
Duration of current episode >2 years, n (%)“3 (15.8)”View highlighted excerpt for this quote
Failed treatments in current episode: 2, n (%)“12 (63.2)”View highlighted excerpt for this quote
Failed treatments in current episode: 3 or 4, n (%)“7 (36.8)”View highlighted excerpt for this quote
Ongoing sertraline, n (%) [min dose, max dose]“6 (31.6) [50 mg, 200 mg]”View highlighted excerpt for this quote
Ongoing escitalopram, n (%) [min dose, max dose]“6 (31.6) [5 mg, 20 mg]”View highlighted excerpt for this quote
Ongoing fluoxetine, n (%) [min dose, max dose]“3 (15.8%) [20 mg, 80 mg]”View highlighted excerpt for this quote
Ongoing vilazodone, n (%) [min dose, max dose]“2 (10.5%) [20 mg, 40 mg]”View highlighted excerpt for this quote
Ongoing paroxetine, n (%) [dose]“1 (5.3%) [60 mg]”View highlighted excerpt for this quote
Ongoing citalopram, n (%) [dose]“1 (5.3%) [20 mg]”View highlighted excerpt for this quote
Duration of SSRI treatment prior to Baseline, months, mean (SD)“14.68 (13.213)”View highlighted excerpt for this quote
MADRS total score, mean (SD)“31.7 (5.77)”View highlighted excerpt for this quote
MADRS moderate (20 to 30), n (%)“7 (36.8)”View highlighted excerpt for this quote
Efficacy results
Health-related quality of life and patient-reported outcomes
Safety results
Treatment-emergent adverse events from Day 1 to Week 3, safety analysis set
Period and eventParticipants, n (%)Events
Overall: any TEAE“12 (63.2)”View highlighted excerpt for this quote“17”View highlighted excerpt for this quote
Overall: any severe TEAE“2 (10.5)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote
Overall: any serious TEAE“0”View highlighted excerpt for this quote“0”View highlighted excerpt for this quote
Day 1: any TEAE“9 (47.4)”View highlighted excerpt for this quote“11”View highlighted excerpt for this quote
Day 1: headache“4 (21.1)”View highlighted excerpt for this quote“4”View highlighted excerpt for this quote
Day 1: blood pressure increased“3 (15.8)”View highlighted excerpt for this quote“3”View highlighted excerpt for this quote
Day 1: dizziness“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Day 1: dry mouth“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Day 1: fall“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Day 1: skin abrasion“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
After Day 1 to Week 3: any TEAE“4 (21.1)”View highlighted excerpt for this quote“6”View highlighted excerpt for this quote
After Day 1 to Week 3: headache“2 (10.5)”View highlighted excerpt for this quote“2”View highlighted excerpt for this quote
After Day 1 to Week 3: depression“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
After Day 1 to Week 3: diarrhea“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
After Day 1 to Week 3: palpitations“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
After Day 1 to Week 3: vertigo“1 (5.3)”View highlighted excerpt for this quote“1”View highlighted excerpt for this quote
Study limitations
Summary: open-label single-arm design, small sample, short follow-up, blood pressure measurement, sponsor analysis

The authors state that the study was limited by its small size, open-label design and absence of a comparator, a sample that was not demographically diverse, and the exclusion of participants with high suicide risk or current hospitalization, and that the open-label design may have influenced participant expectations. Nineteen participants were dosed, no formal sample size calculation was performed, efficacy was summarized descriptively, and follow-up lasted three weeks. Blood pressure elevations were recorded with a finger cuff system that was not accurately calibrated. The sponsor performed the data review, interpretation, and post hoc analyses, and several authors are current or past employees of COMPASS Pathfinder. The authors state that the findings need confirmation in a larger, double-blind, comparator-controlled study.